TGFBR1 and chronic kidney disease: In vivo studies also demonstrated that OCA inhibited the activation of the TGFBR1/TAK1 pathway, thereby postponing the formation of vascular calcification in CKD rats; this effect was weakened by antagomiR-135a-5p.